EFS by patient age group, comparing MRD2008 and MRD2014. The treatment outcomes of patients aged 16 to 35 years were remarkably improved. Compared with the 3-year EFS of MRD2008 (n = 30) of 45% (95% CI, 27-62), the 3-year EFS of MRD2014 (n = 34) of 71% (95% CI, 52-83) was significantly improved (P = .038). In contrast, there were no significant difference in 3-year EFS in patients aged 36 to 55 years, 69% (95% CI, 37-87) vs 50% (95% CI, 32-66; P = .508); and with patient aged 56 to 65 years, 37% (95% CI, 9-67) vs 23% (95% CI, 6-48; P = .226), respectively.